Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Rebecca Bakker-Arkema"'
Autor:
Richard T. George, Liron Abuhatzira, Susan M. Stoughton, Sotirios K. Karathanasis, Dewei She, ChaoYu Jin, Nicholas A. P. S. Buss, Rebecca Bakker‐Arkema, Emily L. Ongstad, Michael Koren, Boaz Hirshberg
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 10, Iss 13 (2021)
Background MEDI6012 is recombinant human lecithin cholesterol acyltransferase, the rate‐limiting enzyme in reverse cholesterol transport. Infusions of lecithin cholesterol acyltransferase have the potential to enhance reverse cholesterol transport
Externí odkaz:
https://doaj.org/article/1a70f3f882f34faebeab6817f3357b2e
Autor:
Michael J. Koren, ChaoYu Jin, Rebecca Bakker-Arkema, Liron Abuhatzira, Dewei She, Boaz Hirshberg, Richard T George, Emily L. Ongstad, Nicholas A P S Buss, Susan M Stoughton, Sotirios K. Karathanasis
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background MEDI6012 is recombinant human lecithin cholesterol acyltransferase, the rate‐limiting enzyme in reverse cholesterol transport. Infusions of lecithin cholesterol acyltransferase have the potential to enhance reverse cholesterol transport
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41ba2d209839d960299a3b3593e85a51
https://doi.org/10.1161/jaha.119.014572
https://doi.org/10.1161/jaha.119.014572
Autor:
Maria Cristina Foss-Freitas, Rebecca Bakker-Arkema, Adam H. Neidert, Thomas L. Chenevert, Baris Akinci, Mario Swaidan, Yingying Luo, Rita Hench, Charles L. Bisgaier, Amy Longcore, Elif A. Oral
Publikováno v:
Diabetes. 69
Familial Partial Lipodystrophy (FPLD) is characterized by partial loss of subcutaneous fat accompanied by metabolic abnormalities, not responding well to conventionally available therapies. Gemcabene calcium is a monocalcium salt of a dialkyl ether d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::42ccc657139cb300afbc4efa8a945ef1
https://doi.org/10.2337/db20-2214-pub
https://doi.org/10.2337/db20-2214-pub
Autor:
Robert A. Hegele, Norman E. Lepor, Evan A. Stein, Rebecca Bakker-Arkema, Liz Masson, Charles Bisgaier, Ronen Durst, Lee Golden, John J.P. Kastelein, Daniel Gaudet
Publikováno v:
American journal of cardiology, 124(12), 1876-1880. Elsevier Inc.
Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder characterized by severely elevated plasma low-density lipoprotein-cholesterol (LDL-C), and premature atherosclerotic cardiovascular disease. Depending on residual LDL receptor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b4ab6a069c802800e696a94d207ed36
https://pure.amc.nl/en/publications/usefulness-of-gemcabene-in-homozygous-familial-hypercholesterolemia-from-cobalt1(84022de0-ccab-4671-9fa3-51e8b20845c7).html
https://pure.amc.nl/en/publications/usefulness-of-gemcabene-in-homozygous-familial-hypercholesterolemia-from-cobalt1(84022de0-ccab-4671-9fa3-51e8b20845c7).html
Autor:
Brian R. Krause, Alan T. Remaley, Robert D. Shamburek, Lita A. Freeman, Marcelo Amar, Reynold Homan, Bruce J. Auerbach, Rebecca Bakker-Arkema
Publikováno v:
Journal of Clinical Lipidology. 10:356-367
Background Humans with familial lecithin:cholesterol acyltransferase (LCAT) deficiency (FLD) have extremely low or undetectable high-density lipoprotein cholesterol (HDL-C) levels and by early adulthood develop many manifestations of the disorder, in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa1327facf49f8e868f9fdab2e81f309
https://doi.org/10.1016/j.jacl.2015.12.007
https://doi.org/10.1016/j.jacl.2015.12.007
Autor:
Juan Frias, John Kastelein, Rebecca Bakker-Arkema, Liz Masson, Lee Golden, Charles Bisgaier, Evan Stein
Publikováno v:
Circulation. 136
Introduction: Recent large cardiovascular event outcome trials with ezetimibe and a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor added to statins demonstrated benefit from additional LDL-C reduction. Despite availability of approve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a384814dffeaf0aca52464bdbd652091
https://doi.org/10.1161/circ.136.suppl_1.23082
https://doi.org/10.1161/circ.136.suppl_1.23082
Autor:
Steve J. Adelman, Anna Wolska, Marcelo Amar, Robert D. Shamburek, Reynold Homan, Alexandra M. Shamburek, Bruce J. Auerbach, Heidi L. Collins, Rebecca Bakker-Arkema, Brian R. Krause, Alan T. Remaley, Lita A. Freeman, Maureen Sampson
Rationale: Low high-density lipoprotein-cholesterol (HDL-C) in patients with coronary heart disease (CHD) may be caused by rate-limiting amounts of lecithin:cholesterol acyltransferase (LCAT). Raising LCAT may be beneficial for CHD, as well as for fa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2972e5dfa052d1f6b68f7b2cf3674ab8
https://europepmc.org/articles/PMC4740220/
https://europepmc.org/articles/PMC4740220/
Publikováno v:
Journal of the American College of Cardiology. 69:1863
Background: Gemcabene (GEM), an ApoC-III and CRP modulator, showed significant LDL-C, ApoB, TG and hsCRP lowering and trends of glucose lowering in dyslipidemic subjects. In preclinical studies, 3T3L1 differentiated adipocytes treated with 100µM GEM
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7dad31b901407f19675adf0e13c56e37
https://doi.org/10.1016/s0735-1097(17)35252-x
https://doi.org/10.1016/s0735-1097(17)35252-x
Autor:
Evan M. Stein, Donald M. Black, Ernst J. Schaefer, Jose M. Ordovas, Rebecca Bakker-Arkema, Dolores Corella, Juan Pedro-Botet
Publikováno v:
Atherosclerosis. 158:183-193
The response to therapy with hypolipidemic agents shows considerable individual variation. These differences may be due to the interaction of environmental and genetic factors that affect drug bioavailability, receptor function or ligand structure. O
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db3a82d36c854dcf8e5be1752c17ffc6
https://doi.org/10.1016/s0021-9150(01)00410-5
https://doi.org/10.1016/s0021-9150(01)00410-5
Publikováno v:
Atherosclerosis. 149:123-129
Data pooled from 21 atorvastatin clinical trials have been analyzed to establish the safety of reducing low density lipoprotein cholesterol (LDL-C) levels below currently recommended minimum targets in hypercholesterolemic patients. Safety data for a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d28035c277086d164cfeaaa9d685ab92
https://doi.org/10.1016/s0021-9150(99)00294-4
https://doi.org/10.1016/s0021-9150(99)00294-4